Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

INTRODUCTION: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than crizotinib in patients with previously untreated,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Soo, Ross A., Chang, Gee-Chen, Chiu, Chao-Hua, Hayashi, Hidetoshi, Kim, Sang-We, Teraoka, Shunsuke, Goto, Yasushi, Zhou, Jianying, Ho-Fun Lee, Victor, Kim, Dong-Wan, Han, Baohui, Chung Man Ho, James, Lin, Chia-Chi, Lu, Shun, Polli, Anna, Calella, Anna Maria, Martini, Jean-François, Wong, Chew Hooi, Mok, Tony, Kim, Hye Ryun, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200970/
https://www.ncbi.nlm.nih.gov/pubmed/37223611
http://dx.doi.org/10.1016/j.jtocrr.2023.100499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200970/
https://www.ncbi.nlm.nih.gov/pubmed/37223611
http://dx.doi.org/10.1016/j.jtocrr.2023.100499

Ejemplares similares